IL105145A0 - Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection - Google Patents

Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Info

Publication number
IL105145A0
IL105145A0 IL105145A IL10514593A IL105145A0 IL 105145 A0 IL105145 A0 IL 105145A0 IL 105145 A IL105145 A IL 105145A IL 10514593 A IL10514593 A IL 10514593A IL 105145 A0 IL105145 A0 IL 105145A0
Authority
IL
Israel
Prior art keywords
hiv
prevention
treatment
monoclonal antibodies
recombinant human
Prior art date
Application number
IL105145A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL105145A0 publication Critical patent/IL105145A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL105145A 1992-04-01 1993-03-24 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection IL105145A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01

Publications (1)

Publication Number Publication Date
IL105145A0 true IL105145A0 (en) 1993-07-08

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105145A IL105145A0 (en) 1992-04-01 1993-03-24 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Country Status (19)

Country Link
EP (1) EP0577243A3 (de)
JP (1) JPH06217791A (de)
KR (1) KR950700761A (de)
CN (1) CN1081716A (de)
AU (2) AU3928593A (de)
BG (1) BG99074A (de)
CA (1) CA2093099A1 (de)
CZ (1) CZ239694A3 (de)
FI (1) FI944561L (de)
HU (1) HUT70461A (de)
IL (1) IL105145A0 (de)
MX (1) MX9301858A (de)
NO (1) NO943653L (de)
NZ (1) NZ251582A (de)
RU (1) RU94045907A (de)
SK (1) SK116294A3 (de)
WO (1) WO1993019785A1 (de)
YU (1) YU22693A (de)
ZA (1) ZA932308B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2220114T3 (es) * 1998-10-30 2004-12-01 Novozymes A/S Variantes de proteinas poco alergenicas.
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
JP4922613B2 (ja) * 2003-02-20 2012-04-25 一般財団法人化学及血清療法研究所 モノクローナル抗体製剤の奏効性を向上させる方法
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
WO2015117008A2 (en) * 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
JP6522732B2 (ja) * 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
EP4007605A4 (de) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. Fcrn-antikörper und verfahren zur verwendung davon
WO2021227138A1 (zh) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的单克隆抗体或其抗原结合部分
CN118666967B (zh) * 2024-03-06 2025-03-28 广东医保药业有限公司 多肽及其与头孢噻肟舒巴坦的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853779T2 (de) * 1987-05-29 1995-09-07 Baylor College Medicine Hiv-1 neutralisierende monoklonale antikörper.
EP0311228A3 (de) * 1987-10-09 1990-05-02 Repligen Corporation Rekombinante Polypeptide und ihre Verwendung einschliesslich Nachweisverfahren für AIDS-Virus
WO1990015078A1 (en) * 1989-06-05 1990-12-13 Scott Charles F Jr HUMAN MONOCLONAL ANTIBODIES TO HIV-1MN gp 120
EP0535154A4 (en) * 1990-06-15 1993-12-01 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
EP0624193A1 (de) * 1992-01-29 1994-11-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AAMP-1, ein Protein mit HIV-1 Env und Nef Proteinen lokalen Homologien

Also Published As

Publication number Publication date
EP0577243A3 (de) 1994-11-02
FI944561A7 (fi) 1994-09-30
RU94045907A (ru) 1996-11-10
FI944561A0 (fi) 1994-09-30
NZ251582A (en) 1997-07-27
JPH06217791A (ja) 1994-08-09
FI944561L (fi) 1994-09-30
YU22693A (sh) 1997-01-08
BG99074A (bg) 1995-11-30
CA2093099A1 (en) 1993-10-02
AU658987B2 (en) 1995-05-04
CZ239694A3 (en) 1995-07-12
KR950700761A (ko) 1995-02-20
HU9402824D0 (en) 1994-11-28
MX9301858A (es) 1994-03-31
EP0577243A2 (de) 1994-01-05
AU3928593A (en) 1993-11-08
CN1081716A (zh) 1994-02-09
HUT70461A (en) 1995-10-30
NO943653D0 (no) 1994-09-30
NO943653L (no) 1994-11-30
SK116294A3 (en) 1996-11-06
WO1993019785A1 (en) 1993-10-14
AU3563093A (en) 1993-10-07
ZA932308B (en) 1994-09-30

Similar Documents

Publication Publication Date Title
EP0831873A4 (de) Die behandlung von hiv und anderen viralen infektionen mit der kombinationstherapie
GB9019812D0 (en) Novel antibodies for treatment and prevention of infection in animals and man
ZA932308B (en) Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
EP0584558A3 (de) Zusammensetzung zum Unterdrücken von Infektion und Wachstum des menschlichen Immunschwäche-Virus unter Verwendung eines eisenbindenden Proteins.
GB9207479D0 (en) Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
HUT44619A (en) Process for preparing monoclonal antibodies and peptides suitable for the treatment and detection of hiv infections
AU4028895A (en) Vaccine and treatment method of Human Immunodeficiency Virus
EP0531365A4 (en) Diagnosis and treatment of viral hepatitis
GB9304746D0 (en) Treatment of viral infections
EP1202750A4 (de) Verfahren zur behandlung von hiv-infektionen und von deren opportunistischen infektionen
EP0382551A3 (en) Prevention and treatment of herpes virus infections
AU591017B2 (en) Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient
GB9417173D0 (en) Novel treatment of upper respiratory tract infections
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
GB9216360D0 (en) Treatment of blood
HK1013831A (en) Novel antibodies for treatment and prevention of infection in animals and man
HUT68145A (en) Procedure for the treatment and shaping of hair
HK1013665A (en) Antibodies for treatment and prevention of respiratory syncytial virus infection
PH27412A (en) Method of treatment of human immunodeficiency virus
GB2266241B (en) Treatment of pastures
ZA941471B (en) Treatment of viral infections
IE880770L (en) Treatment of viral infections
NZ231322A (en) Treatment of viral and/or bacterial infections
NZ233973A (en) Treatment of viral and/or bacterial infections